search

Active clinical trials for "Primary Myelofibrosis"

Results 81-90 of 315

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With...

Myelofibrosis

The purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.

Active23 enrollment criteria

Decitabine in Treating Patients With Myelofibrosis

Primary MyelofibrosisSecondary Myelofibrosis

This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.

Active32 enrollment criteria

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

MyelofibrosisLeukemia14 more

Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Active41 enrollment criteria

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms...

Myeloproliferative NeoplasmMPN3 more

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

Active21 enrollment criteria

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

MyelofibrosisPrimary Myelofibrosis2 more

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Active10 enrollment criteria

Asian Myeloproliferative Neoplasm (MPN) Registry

Myeloproliferative NeoplasmPolycythemia Vera8 more

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

Recruiting12 enrollment criteria

Quantitative MRI for Myelofibrosis

Myelofibrosis

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

Recruiting8 enrollment criteria

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

MyelofibrosisAcute Myelogenous Leukemia

This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-2400 is safe. The second goal is to find out what effects TBX-2400 stem cells have on time to engraftment in adult subjects with AML or MF. The study hypothesis is that TBX-2400 cells will shorten the time to immune reconstitution after transplant.

Not yet recruiting21 enrollment criteria

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Myelofibrosis

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.

Not yet recruiting22 enrollment criteria

Connect® Myeloid Disease Registry

Primary MyelofibrosisMyelodysplastic Syndromes3 more

The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.

Recruiting18 enrollment criteria
1...8910...32

Need Help? Contact our team!


We'll reach out to this number within 24 hrs